nonlinear regression fitting of the inhibition curves using a four-parameter logistic model in graphpad prism 8.0 (GraphPad Software Inc)
GraphPad Software Inc is a verified supplier 
90
Structured Review
GraphPad Software Inc
nonlinear regression fitting of the inhibition curves using a four-parameter logistic model in graphpad prism 8.0
Nonlinear Regression Fitting Of The Inhibition Curves Using A Four Parameter Logistic Model In Graphpad Prism 8.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonlinear+regression+fitting+of+the+inhibition+curves+using+a+four-parameter+logistic+model+in+graphpad+prism+8%2E0/nonlinear+regression+fitting+of+the+inhibition+curves+using+a+four+parameter+logistic+model+in+graphpad+prism+8+0/pm40639288-277-18-30
Average 90 stars, based on 1 article reviews
Nonlinear Regression Fitting Of The Inhibition Curves Using A Four Parameter Logistic Model In Graphpad Prism 8.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nonlinear+regression+fitting+of+the+inhibition+curves+using+a+four-parameter+logistic+model+in+graphpad+prism+8%2E0/nonlinear+regression+fitting+of+the+inhibition+curves+using+a+four+parameter+logistic+model+in+graphpad+prism+8+0/pm40639288-277-18-30
Average 90 stars, based on 1 article reviews
nonlinear regression fitting of the inhibition curves using a four-parameter logistic model in graphpad prism 8.0 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Inhibition:Article Title: Development of Thieno[3,2-d]pyrimidine derivatives as potent RIPK2 inhibitors with Prominent In vitro and In vivo anti-inflammatory efficacy. Article Snippet: Acute liver injury (ALI) is a major pathological event in various liver diseases and remains a significant global medical challenge in terms of prevention and treatment.. RIPK2, as a novel therapeutic target, has shown promise in the treatment of various inflammatory diseases, and it also holds potential for addressing acute liver injury.. In this study, starting from a patent compound, computer-aided drug design and targeted structural optimization were employed to develop a new RIPK2 inhibitor with a thieno[3,2-d]pyrimidine core scaffold. |